CureVac Collaborate with UK Government to Develop Vaccines Against SARS-CoV-2 variants

 CureVac Collaborate with UK Government to Develop Vaccines Against SARS-CoV-2 variants

CureVac Commences P-llb/lll Trial of CVnCoV for COVID-19

Shots:

  • The collaboration combines expertise, resources and technology from both parties to develop and manufacture variant vaccines against SARS-CoV-2 variants. CureVac is expected to supply 50M doses of variant vaccines to the UK, following the regulatory approval
  • The VTF and the CureVac will deploy mRNA platform to assess multiple SARS-CoV-2 variants and are expected to generate vaccine candidates against selected ones
  • Additionally, CureVac will transfer its technology to enable the manufacturing of clinical & commercial quantities of any vaccines that result from the collaboration, as well as manufacturing of CureVac’s existing vaccine against SARS-CoV-2 (CVnCoV), currently in P-III study

Click here ­to­ read full press release/ article | Ref: CureVAc | Image: CureVAc

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post